Albumin Market Outlook Signals Expansion To $10.61 Billion Through 2030

The albumin market is on the verge of notable expansion as advancements in biotechnology and growing applications in healthcare continue to emerge. With increasing adoption in therapeutic and cosmetic sectors, this industry is set to experience substantial growth through 2030. The following sections provide a detailed insight into the market size, key players, emerging trends, and major segments shaping the future of the albumin industry.

Projected Growth Trajectory of the Albumin Market by 2030
The albumin market is anticipated to reach a value of $10.62 billion by 2030, growing at a steady compound annual growth rate (CAGR) of 8.0%. This upward trend is supported by technological progress in recombinant albumin production, rising demand for personalized medicine approaches, and the expanding role of albumin in drug delivery systems. Additionally, growth in biopharmaceutical manufacturing and increased investments in therapeutic and cosmetic uses are significant contributors to this market expansion. Key trends during the forecast period include the rising therapeutic applications of human serum albumin, broader use of albumin in vaccines and drug formulations, and growing incorporation of recombinant albumin in biopharma, diagnostics, and cell culture technologies.

The albumin market size has grown strongly in recent years. It will grow from $7.16 billion in 2025 to $7.81 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to limited availability of plasma-derived albumin, growing prevalence of liver diseases and burns, increasing use in diagnostic kits, rising biopharmaceutical R&D activities, early adoption in laboratory and research applications.

Download a free sample of the albumin market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16333&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Factors Catalyzing Growth in the Albumin Market
The demand for human serum albumin, particularly in therapeutic settings, continues to gain momentum, driven by its efficacy in treating a range of medical conditions. This increasing utilization is complemented by albumin's expanding function in drug formulations and vaccines, which is helping to diversify its applications.
Simultaneously, recombinant albumin is carving out a larger presence in the biopharmaceutical sector, thanks to advancements that enhance its safety profile and functionality. The growing emphasis on personalized medicine and diagnostic innovation also supports further uptake of albumin-based products, highlighting the versatile role this protein plays across healthcare domains.

Leading Industry Players Defining the Albumin Market Landscape
The albumin market features several prominent companies, including Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., CSL Limited, Grifols SA, Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Kedrion S.p.A., Biotest AG, Jiangxi Boya Bio-Pharmaceutical Co. Ltd., BPL (Bio Products Laboratory), Kamada Ltd., Proliant Biologicals, SeraCare Life Sciences Inc., HiMedia Laboratories, Albumedix Ltd., Medxbio Pte Ltd., Ventria Bioscience Inc., and China Biologic Products Holdings Inc.

View the full albumin market report:
https://www.thebusinessresearchcompany.com/report/albumin-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Strengthening Collaborations to Advance Recombinant Albumin Availability
In November 2025, Evonik Industries AG, a specialty chemicals firm based in Germany, formed a strategic partnership with InVitria to enhance global access to animal-component-free recombinant human serum albumin (rHSA). This collaboration aims at boosting Evonik's biologics and cell therapy portfolio by incorporating InVitria's high-purity recombinant albumin into its product offerings. InVitria, a US biotechnology company, specializes in producing animal-free recombinant proteins used in vaccines, cell culture, and therapeutic development, supporting safer and more sustainable biopharmaceutical applications.

Latest Innovations Shaping the Albumin Market
Industry leaders are innovating by developing recombinant albumin that is free from both animal and human origins, produced using non-mammalian systems such as yeast. This approach ensures purity and reduces risks associated with traditional sources.
For example, in March 2023, Albumedix, a UK-based recombinant human albumin manufacturer, partnered with Japan's Heartseed Inc., a clinical-stage biotech company, to introduce Recombin-an essential excipient for Heartseed's investigational cell therapy HS-001, which entered its first-in-human clinical trial. This milestone highlights the pivotal role of recombinant albumin in enhancing the stability and effectiveness of cutting-edge cell therapies.

Market Segmentation Overview Highlighting Albumin's Diverse Applications
The albumin market can be divided into several main categories:
1) By Type: Human Serum Albumin, Bovine Serum Albumin, and Recombinant Albumin
2) By Application: Therapeutics, Drug Formulations and Vaccines, Components of Media, and Other Uses
3) By End-User: Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, and Research Institutes

Breaking down these categories further:
- Human Serum Albumin includes plasma-derived, recombinant variants, therapeutic uses for conditions like liver disease and burns, as well as drug delivery and research applications.
- Bovine Serum Albumin serves laboratory functions such as cell culture, diagnostic kits, and acts as a stabilizer in vaccines and biopharmaceutical products.
- Recombinant Albumin is utilized in therapeutic treatments, biopharmaceutical formulations, cosmetic and personal care products, and various research and diagnostic applications.

Comprehensive Regional Perspectives Fueling the Albumin Market Outlook
Although the report mainly focuses on global market dynamics, the ongoing expansion is driven by advancements in biopharmaceutical manufacturing hubs worldwide. Increasing investments in recombinant protein technologies and personalized medicine in regions such as North America, Europe, and Asia-Pacific contribute to the robust trajectory of the albumin market.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.